Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
US FDA Accepts Relugolix for Review in Advanced Prostate Cancer
Myovant Sciences, a subsidiary of Sumitomo Dainippon Pharma, said on June 22 that the US FDA has accepted for review its new drug application (NDA) for relugolix for the treatment of men with advanced prostate cancer. The drug has been…
To read the full story
Related Article
- US Approves Myovant’s Relugolix Combo for Uterine Fibroids
May 28, 2021
- US FDA Accepts Myovant’s Relugolix Triple Combo for Review in Uterine Fibroids
August 19, 2020
- Relugolix Combo Filed in US for Uterine Fibroids
June 3, 2020
- Myovant Files Relugolix for Advanced Prostate Cancer in US
April 23, 2020
BUSINESS
- Espha to Reinvest AG Profits into New Biz after Reform; Xarelto AG Logs 19 Billion Yen
May 15, 2026
- Meiji Opposes French Fund’s Push to Review Pharma Spin-Off
May 15, 2026
- FRONTEO Opens AI Drug Discovery Lab, Pivots to Out-Licensing Model
May 15, 2026
- Inqovi-Venetoclax Combo Wins FDA Approval in AML: Taiho
May 15, 2026
- Chugai Files Gazyva for Idiopathic Nephrotic Syndrome in Japan
May 15, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…